An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects with Androgenetic Alopecia
Latest Information Update: 01 Feb 2025
At a glance
- Drugs VDPHL (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Veradermics
Most Recent Events
- 22 Jan 2025 Planned number of patients changed from 20 to 70.
- 22 Jan 2025 Planned End Date changed from 1 Aug 2025 to 31 Mar 2026.
- 22 Jan 2025 Planned primary completion date changed from 1 Aug 2025 to 28 Feb 2026.